Abbott vs Danaher: which healthcare stock looks better positioned following earnings? Published on august 4, 2026 at 12:55 pm by noor ul ain rehman in hedge funds, news. Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Danaher Corporation's (NYSE:DHR) second-quarter results, on the other hand, were marked by core growth improving compared to the previous quarter, along with disciplined execution that drove high-single-digit adjusted EPS growth. Let's take a closer look at which company appears better positioned for future growth following their latest quarterly results. Abbott Laboratories (NYSE:ABT) reported GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items, and reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%, suggesting confidence in its operations. The company also raised its full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to the previous range of $5.38 to $5.58. Key fiscal Q2 2026 results for Danaher Corporation (NYSE:DHR) included a 5.5% year-over-year growth in revenue to $6.3 billion, as well as a 60% year-over-year rise in net earnings to $870 million, or $1.23 per diluted common share. The company also reported that non-GAAP core revenue increased 3.0% year-over-year and non-GAAP core revenue, excluding respiratory testing revenue, increased 4.5% year-over-year, suggesting improving trends in the company's operations. According to LSEG data, Danaher Corporation's (NYSE:DHR) adjusted EPS of $1.94 exceeded analyst estimates of $1.83. Bull case. One of the biggest highlights of the quarter for Abbott Laboratories (NYSE:ABT) was its diagnostics segment. The company's cancer diagnostics business, which was recently integrated through the Exact Sciences buyout, is benefiting from an expanding base that comprises both new and repeat users of the colorectal cancer screening test, Cologuard. Sales in its diagnostics segment rose 42% to $3.09 billion in fiscal Q2, surpassing the estimate of $3.02 billion, emerging as one of the company's strongest performers during the quarter. Analysts agree with this sentiment. William Blair stated that the company's cancer diagnostics results should improve sentiment around the Exact Sciences acquisition, with growth in medical devices helping offset concerns surrounding hospital procedure volumes. The firm reiterated an Outperform rating on the shares and noted that its shares rose over 10% on fiscal Q2 results, which helps alleviate concerns surrounding the recent Exact Sciences acquisition and medtech end markets, and signals an improving nutrition business. It told investors in a research note that all of these updates were positive, and should compound with pipeline products for even better results in H2 2026 and into FY27. In contrast, Danaher Corporation's (NYSE:DHR) biggest positive was its Life Sciences business, which delivered its strongest performance in several years. Although bioprocessing revenue was affected by customer project timings, the underlying order trends remained strong, with bioprocessing orders growing mid-teens in the quarter. This shows that the underlying demand for bioprocessing remained strong, which includes consumables and equipment necessary to make biologic drugs. Danaher Corporation (NYSE:DHR) stated that a little over $100 million of revenue has shifted into next year, primarily from the second and third quarters. This suggests that customer demand has been delayed rather than cancelled, potentially supporting future revenue growth. While the academic and government markets have largely stabilized, more supportive government policies would be essential to safely call it an inflection point. Bear case. However, Danaher Corporation (NYSE:DHR) reported weaker-than-expected revenue in its biotechnology business and cut its full-year core revenue growth outlook. The company cut the upper end of its core revenue growth outlook range to 4% from 6% for the year, and maintained the lower end at 3%, primarily to take into account the effects of the weaker respiratory testing revenue. These trends overshadowed the improving trends in the life sciences tools market at a time when pharmaceutical and biotech companies are increasing research and manufacturing spending following the post-pandemic slowdown. Following the earnings, BofA told investors that while the overall total company numbers were "fine" and ahead of expectations, the result "was certainly messier than expected", driven primarily by a miss in bioprocessing that caused the stock to tumble 11%. While the firm maintained a Buy rating on Danaher Corporation (NYSE:DHR), it cut the price target on the stock to $230 from $270, stating that the company now has to rebuild confidence in the execution and business. This holds especially true as "this is not the first setback/headwind to pop up in recent years" for the company. On the other hand, while Abbott Laboratories' (NYSE:ABT) outlook remains encouraging, a meaningful portion of its expected growth acceleration in the second half of 2026 depends on the successful commercialization of several pipeline products. Management has expressed confidence that sales and earnings growth will accelerate in the second half of 2026. While this outlook is supported by improving momentum across multiple business segments, investors will need to see that acceleration materialize over the coming quarters. Notably, Abbott Laboratories (NYSE:ABT) reaffirmed rather than raised its full-year comparable sales growth guidance of 6.5% to 7.5%, suggesting that management remains prudent despite its strong second-quarter performance. What does hedge fund ownership say? Hedge fund ownership for the two stocks provides additional insight into the investment thesis. According to Insider Monkey's database of 1,022 hedge funds, hedge fund sentiment for the stock has improved moderately from the previous quarter, rising from 71 in fiscal Q4 2025 to 73 in fiscal Q1 2026. While the increase is modest, it suggests that institutional investors continue to maintain confidence in Abbott Laboratories' (NYSE:ABT) long-term growth prospects following its strong quarterly performance. However, according to Insider Monkey's extensive database tracking 1,022 hedge funds, Danaher Corporation's (NYSE:DHR) hedge fund ownership dropped from 125 in fiscal Q4 2025 to 110 in fiscal Q1 2026. The total dollar value also dropped from $11.42 billion to $10.11 billion, suggesting that some institutional investors have become more cautious amid the company's recent execution challenges. What investors should watch next. William Blair highlighted the key pipeline products to watch for Abbott Laboratories (NYSE:ABT), which include the launch of Amulet 360 late in the year or early in 2027, the ramping-up launch of Volt in the U.S. and TactiFlex Duo OUS, and the potential for Libre reimbursement expansion. For Danaher Corporation (NYSE:DHR), investors should watch bioprocessing order growth over the coming quarters. If delayed revenues begin flowing into next year as management expects, investor confidence could improve significantly. Management also expects 3%-4% core revenue growth for fiscal 2026, making execution in its Life Sciences segment an important factor to monitor. Sustained momentum and execution in the life sciences segment could also offset weakness elsewhere in the portfolio for the company. While we acknowledge the potential of DHR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than DHR and that has 100x upside potential, check out our report about the cheapest AI stock. Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds' investor letters by entering your email address below. Related Insider Monkey Articles

Danaher taps Julie Sawyer Montgomery as next CEO. The diagnostics leader will take over on October 1 as Rainer Blair retires, with Danaher keeping its quarterly and full-year outlook unchanged. 35 minutes ago - 2 mins What's going on here? Danaher just picked Julie Sawyer Montgomery, a longtime executive, as its next CEO, with current chief Rainer Blair retiring and the handoff set for October 1. What does this mean? The timing matters because Danaher's business has been telling two different stories: diagnostics has held up well, while its biotechnology tools unit has recently come in softer than investors expected. That's notable in a broader life sciences tools market where biotech and drugmakers have been slowly increasing spending again after a post-pandemic lull, putting more weight on execution. Rather than using the transition to reset expectations, Danaher said there's no change to it... Keep reading for free. This content is free, but you must be logged in to continue reading. Already have an account?

Johnson & Johnson reported strong Q2 2026 results with sales rising nearly 7% to $25.31 billion, beating estimates of $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expected $2.85. The company raised its full-year guidance and remains on track to exceed $100 billion in annual revenue for the first time in its 140-year history. Its pharmaceutical division generated $16.38 billion in quarterly sales. Despite a 55% drop in Stelara revenue to $740 million due to patent loss, newer drugs compensated for the decline. Tremfya sales surged 72.5% to $2 billion, well above the $1.74 billion estimate. Meanwhile, Danaher delivered encouraging Q2 results driven by its Life Sciences business, with bioprocessing orders growing mid-teens despite timing-related revenue fluctuations.